AHA Video: Ticagrelor may negate the need to assess genetic variations
Click to play
AHA Video: Paul A. Gurbel, MD
Center for Thrombosis Research at Sinai Hospital
Baltimore, MD
CHICAGO--Paul A. Gurbel, MD, from the Center for Thrombosis Research at Sinai Hospital in Baltimore, who was the principal investigator of the ONSET/OFFSET and RESPOND studies, reviews findings from new genotyping analyses, which show genotype variations and metabolizer status does not affect platelet inhibition for patients taking ticagrelor (Brilinta, AstraZeneca).

Gurbel also speaks to how these outcomes could affect real-life clinical practice, if the antiplatelet agent is approved.

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.

Trimed Popup
Trimed Popup